二氧化碳剥脱性点阵激光技术在光动力治疗尖锐湿疣中的应用研究

Application of carbon dioxide ablative fractional laser in photodynamic therapy for condylomata acuminata

  • 摘要:
    目的 探讨二氧化碳剥脱性点阵激光(CO2-AFL)技术在光动力(PDT)治疗尖锐湿疣(CA)中的应用效果。
    方法 将2022年1月—2023年12月80例CA患者随机分为2组, 每组40例。对照组采用以5-氨基酮戊酸(5-ALA)为光敏剂的PDT疗法(5-ALA-PDT),研究组采用二氧化碳剥脱性点阵激光(CO2-AFL)联合5-ALA-PDT治疗, 2组均治疗4周。比较2组临床疗效、复发情况及不良反应发生情况; 比较2组治疗前及治疗4周后血清炎症因子相关指标、免疫功能相关指标、局部人乳头瘤病毒(HPV)载量、皮肤病生活质量指数量表(DLQI)评分。
    结果 研究组总有效率为97.50%, 高于对照组的80.00%, 差异有统计学意义(P < 0.05)。治疗4周后, 2组白细胞介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)水平均较治疗前降低, γ干扰素(IFN-γ)、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)、辅助型T细胞1与辅助型T细胞2比值(Th1/Th2)均较治疗前升高,且研究组IL-2、TNF-α水平低于对照组,IFN-γ、IL-4、IL-10、Th1/Th2水平高于对照组,差异均有统计学意义(P < 0.05)。治疗4周后, 2组CD8+较治疗前下降, CD3+、CD4+、CD4+/CD8+均较治疗前提高, 且研究组CD3+、CD4+、CD4+/CD8+水平高于对照组, CD8+水平低于对照组, 差异均有统计学意义(P < 0.05)。治疗4周后, 2组局部HPV载量及DLQI评分均较治疗前降低,且研究组低于对照组,差异有统计学意义(P < 0.05)。研究组和对照组不良反应发生率分别为10.00%和5.00%, 差异无统计学意义(P>0.05); 研究组6个月内复发率为5.00%, 低于对照组的22.50%, 差异有统计学意义(P < 0.05)。
    结论 CO2-AFL技术应用于5-ALA-PDT治疗CA中疗效确切,有助于杀灭潜伏HPV病毒,改善机体炎症因子水平,促进机体免疫功能恢复,提高CA患者生活质量,且复发率低。

     

    Abstract:
    Objective To explore the application effect of carbon dioxide ablative fractional laser (CO2-AFL) in photodynamic therapy (PDT) for condylomata acuminata (CA).
    Methods A total of 80 patients with CA from January 2022 to December 2023 were randomly divided into two groups, with 40 cases in each group. Control group was treated with PDT mediated by 5-aminolevulinic acid (5-ALA) as a photosensitizer (5-ALA-PDT), while study group was treated with CO2-AFL combined with 5-ALA-PDT. Both groups were treated for 4 weeks. Clinical efficacy, recurrence, and adverse reactions were compared between the two groups; additionally, serum inflammatory factors, immune function related indicators, local human papillomavirus (HPV) load, and the Dermatology Life Quality Index (DLQI) scores before treatment and 4 weeks after treatment were compared between the two groups.
    Results The total effective rate was 97.50% in the study group, which was significantly higher than the 80.00% in the control group (P < 0.05). Four weeks after treatment, the levels of interleukin-2 (IL-2) and tumor necrosis factor-α (TNF-α) decreased significantly in both groups when compared with before treatment, while the levels of interferon-γ (IFN-γ), interleukin-4 (IL-4), interleukin-10 (IL-10), and the ratio of T helper 1 to T helper 2 cells (Th1/Th2) increased significantly when compared with before treatment (P < 0.05); moreover, the levels of IL-2 and TNF-α in the study group were significantly lower than those in the control group, while the levels of IFN-γ, IL-4, IL-10, and Th1/Th2 in the study group were significantly higher than thosein the control group (P < 0.05). Four weeks after treatment, CD8+ level significantly decreased in both groups when compared with before treatment, while CD3+, CD4+, and CD4+/CD8+ levels increased significantly when compared with before treatment (P < 0.05); additionally, the levels of CD3+, CD4+ and CD4+/CD8+ in the study group were significantly higher than those in the control group, while CD8+ level was significantly lower in the study group (P < 0.05). Four weeks after treatment, the local HPV load and DLQI score significantly decreased in both groups when compared with those before treatment, and these indexes in the study group were significantly lower than those in the control group (P < 0.05). The incidence of adverse reactions was 10.00% in the study group, which showed no significant difference when compared to 5.00% in the control group (P>0.05). The recurrence rate within 6 months was 5.00% in the study group, which was significantly lower than the 22.50% in the control group (P < 0.05).
    Conclusion Application of CO2-AFL in 5-ALA-PDT for CA is effective, which helps to eliminate latent HPV viruses, improve serum levels of inflammatory factors, promote the recovery of immune function, and improve the quality of life of CA patients, with a low recurrence rate.

     

/

返回文章
返回